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ABSTRACT
The main aim of this study was to evaluate the clinical outcome and costs of nosocomial and
community-acquired methicillin-susceptible Staphylococcus aureus (MSSA) or methicillin-resistant
S. aureus (MRSA) bloodstream infection (BSI) in patients undergoing haemodialysis. A multicentre
retrospective study was conducted that included 109 patients with end-stage renal disease and S. aureus
BSI who were hospitalised in three German centres between 1999 and 2005. Nosocomial and
community-acquired infections were analysed separately with regard to costs and outcome. Forty-nine
(45%) patients had nosocomial infection. Compared to patients with community-acquired infection,
these patients were more likely to have had BSI caused by MRSA (40.8% vs. 13.3%, p <0.05). BSI was the
initial reason for admission for 33 (55%) patients who had community-acquired infection. The mean
length of hospitalisation was 24 days for patients with community-acquired infection and 51 days for
patients with nosocomial infection (p <0.05). Costs per treatment episode were 20 024 Euros for
nosocomial infection vs. 9554 Euros for community-acquired infection (p <0.05). The average treatment
costs for patients with MSSA BSI were <50% of those for patients with MRSA BSI (10 573 vs. 24 931
Euros, p <0.05). S. aureus BSI is an underlying cause of substantial health risk and high morbidity among
the haemodialysis-dependent population, who are already at high-risk for other reasons. This study also
highlighted differences according to the source of BSI, including costs arising from hospitalisation and
treatment.
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INTRODUCTION
Staphylococcus aureus is a common cause of
community-acquired and nosocomial infections,
e.g., bacteraemia or bloodstream infection (BSI),
wound infections, metastatic abscesses, endocar-
ditis, osteomyelitis and septic arthritis [1–5].
Patients with end-stage renal disease are partic-
ularly susceptible to such infections [6,7]. The
risk to patients undergoing dialysis of acquiring
invasive S. aureus infections is estimated at 3–4%
annually [6,8], i.e., 2–10-fold higher than for the
general population [7]. In patients with tun-
nelled, cuffed haemodialysis catheters, the inci-
dence of S. aureus BSI has been estimated to be
0.6–3.9 ⁄ 1000 catheter-days [9,12]. An increasing
proportion of S. aureus isolates is resistant to
various antibiotics [1,13–19]. In 2003, c. 20% of
all S. aureus isolates in Germany were methicil-
lin-resistant S. aureus (MRSA) (EARSS Annual
Report 2003; http://www.earss.rivm.nl). Despite
technological improvements and measures taken
to decrease the spread of MRSA, S. aureus
infection remains a serious and frequent compli-
cation of haemodialysis [20]. Accordingly, the
aims of this retrospective study were to investi-
gate the clinical outcome and economic conse-
quences of S. aureus BSI among a cohort of
haemodialysis patients.
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PATIENTS AND METHODS
This multicentre retrospective study was based on treatment
data from adult patients with end-stage renal disease who
were undergoing chronic haemodialysis and who were admit-
ted with S. aureus BSI to three centres (University Hospital
of Erlangen-Nurnberg, University Hospital of Cologne and
University Hospital of Regensburg, Germany) between
December 1999 and May 2005. Pooled data from these three
centres were considered to be representative of German
haemodialysis patients with S. aureus infection.
The data collection procedures and the deﬁnitions of
patient characteristics were essentially as described previously
[9]. Exclusion criteria included S. aureus infection in non-
hospitalised patients, age <18 years, and polymicrobial infec-
tion. Patients with S. aureus BSI for whom data were not
available were also excluded from this analysis.
Patient treatment data were analysed for up to 12 weeks
following admission to the hospital or until death. Patient
characteristics collected and analysed included age, gender,
co-morbidities, type of kidney disease, type of haemodialysis
access, signs and symptoms at admission, primary reason for
admission, and presumed source and type of S. aureus BSI.
S. aureus BSI was deﬁned as community-acquired if positive
blood cultures were detected within 72 h of admission, and
nosocomial if detected ‡72 h after admission. The deﬁnition of
community-acquired S. aureus BSI also included the possibility
of healthcare-associated infection before admission. S. aureus
BSI complications and outcome (mortality during stay and
after 12 weeks) were analysed.
An analysis of diagnostic and therapeutic procedures,
treatment duration and costs was also carried out. Costs were
expressed in terms of hospital costs attributable to S. aureus
infection during hospitalisation, and costs of other BSI-related
medical services provided after discharge. Outpatient care
costs and re-hospitalisation costs were included only for
procedures and admissions related to S. aureus infection
during the 12 weeks following detection of S. aureus infection.
Only direct medical costs were considered in the analysis.
Hospital costs were calculated on the basis of the treatment
cost data, based on the reimbursement rates (diagnosis-related
ﬂat-rate per case) of the G-DRG (German reﬁned diagnosis-
related groups) for the period after 2003, and hospital per diem
charges for the period before 2003. Outpatient care drug costs
were based on the German pharmaceutical register ‘Rote Liste
2005’.
Statistical analyses of patient data were performed using
SPSS v.12.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics
are presented as counts and percentages for discrete variables.
Continuous variables are reported as means ± SD. The differ-
ences among groups were analysed with Student’s t-test for
continuous variables or the chi-square test for discrete varia-
bles, using the standard level of signiﬁcance (p 0.05).
RESULTS
Between March 1995 and May 2005, 109 haemo-
dialysis patients with S. aureus BSI were identiﬁed
(65 individuals at the University Hospital of
Erlangen-Nurnberg, 36 individuals at the Univer-
sity Hospital of Cologne, and nine individuals at
the University Hospital of Regensburg). Patient
characteristics are summarised in Table 1. Pa-
tients with nosocomial infection were infected
more frequently with MRSA than patients with
community-acquired infection, i.e., 41% and 13%,
respectively (p <0.05). Forty-three (39%) patients
received a penicillin agent with a b-lactamase
inhibitor as antibiotic therapy. Twenty-nine
(26.6%) patients were treated with vancomycin,
16 of whom had MRSA infection. The duration of
antimicrobial therapy varied from 1 to 109 days
(mean 18.41 ± 19.04 days). Nearly half of the
patients were treated with antibiotics for
<14 days.
Table 1. Characteristics of haemodialysis patients with
Staphylococcus aureus bloodstream infectiona
Characteristics
Nosocomial
(n = 49)
Community-
acquired
(n = 60)
Total
(n = 109)
Age, years, mean ± SD 66.54 ± 11.62 62.58 ± 14.27 64.36 ± 13.23
Male 31 (63.3) 37 (61.7) 68 (62.4)
Co-morbidities
Diabetes mellitus 25 (51) 31 (51.7) 56 (51.4)
Injecting drug use 11 (22.4) 14 (23.3) 25 (22.9)
Malignancy 8 (16.3) 5 (8.3) 13 (11.9)
Corticosteroid use 5 (10.2) 5 (8.3) 10 (9.2)
Infection with HIV 0 (0) 3 (5) 3 (2.8)
History of infective endocarditis 0 (0) 1 (1.7) 1 (0.9)
Rheumatoid arthritis 0 (0) 1 (1.7) 1 (0.9)
Characteristics of kidney disease
Presumed aetiology of kidney failureb
Diabetes mellitus 23 (46.9) 26 (43.3) 49 (45)
Hypertension 18 (36.7) 23 (38.3) 41 (37.6)
Glomerulonephritis 9 (18.4) 14 (23.3) 23 (21.1)
Other or unknown 25 (51) 19 (31.7) 40 (36.7)
History of kidney transplantation 6 (12.2) 9 (15) 15(13.8)
Duration of haemodialysis,
years ± SD
2.09 ± 4.52 3.59 ± 4.84 2.94 ± 4.74
Haemodialysis access
(at admission)b
Fistulac 20 (40.8) 39 (65) 59 (54.1)
Tunnelled cuffed catheterc 7 (14.3) 23 (38.3) 30 (29.4)
Graft 2 (4.1) 8 (13.3) 10 (9.2)
Temporary catheter 4 (8.2) 4 (6.7) 8 (7.3)
Implanted subcutaneous
access device
1 (2) 0 (0) 1 (0.9)
No access device at admission 17 0 (0)
Signs and symptoms at admissionb
Fever >38C 48 (98) 60 (100) 108 (99.1)
Septic shock (systolic blood
pressure <90 mm Hg)
11 (22.4) 10 (16.7) 21 (19.3)
Evidence of central nervous
system involvement
2 (4.1) 3 (5) 5 (4.6)
Heart failure 2 (4.1) 2 (3.3) 4 (3.7)
Presumed source of bacteraemia
Haemodialysis access 25 (51) 30 (50) 55 (50.5)
Tissue source 7 (14.3) 9 (15) 16 (14.7)
Other ⁄unknown 17 (34.7) 21 (35) 38 (34.2)
Primary reason for admissionc
Suspected S. aureus infection 5 (10.2) 33 (55) 38 (34.9)
Other medical conditions 39 (79.6) 16 (26.7) 55 (50.5)
Access difﬁculties 3 (6.1) 8 (13.3) 11 (10.1)
Surgical procedures not
related to access difﬁculties
2 (4.1) 3 (5.0) 5 (4.6)
Infection with methicillin-resistant
S. aureusc
20 (40.8) 8 (13.3) 28 (25.7)
aValues are expressed as a number (percentage) unless otherwise indicated.
bSub-categories not mutually exclusive.
cStatistically signiﬁcant (p <0.05). HIV, human immunodeﬁciency virus.
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Complications and outcomes of S. aureus BSI
are summarised in Table 2. Thirty-six (33%)
patients had persistent S. aureus infection at dis-
charge, a signiﬁcant number of whom (16; 44.4%)
had MRSA infection. Treatment, outcome, dur-
ation of stay and costs did not differ signiﬁcantly.
Mortality was similar among patients with meth-
icillin-susceptible S. aureus and MRSA BSI (30.9%
vs. 32.1%, respectively). Diagnostic and surgical
procedures performed for diagnosis and treat-
ment are summarised in Table 3. All procedures
were counted only once in each category, even if
repeated. Most of the surgical procedures were
related to the access device; 64% of patients
underwent at least one such procedure. Only
patients with the corresponding access device
were counted in the sub-categories.
Because of the changes in the German health-
care system, two different remuneration systems
were used during the study (see Patients and
methods). Mean duration and costs, differentiated
according to type of charging and nosocomi-
al ⁄ community-acquired infections, are summa-
rised in Table 4. The largest component of the
total costs (c. 93%) was associated with the initial
period of hospitalisation. The mean costs for
subsequent hospitalisation periods represented
only 6.4% of the total costs. The mean outpatient
costs were negligible (0.825% of the total).
DISCUSSION
This study investigated retrospectively a large
cohort of end-stage renal disease patients with BSI
caused by S. aureus. Most of these infections were
community-acquired. The proportion of patients
with MRSA was signiﬁcantly higher among
patients with nosocomial infection. BSI caused
by MRSA has been identiﬁed as a risk-factor for
death in other studies, but rates of MRSA BSI vary
widely [21]. Overall, the proportion of MRSA
infections was much higher than in a mixed
German cohort of patients with S. aureus BSI
(5%), indicating that patients undergoing haemo-
dialysis have an increased risk of acquiring MRSA
[22]. Engemann et al. [9] reported that 25.7% of
infections were caused by MRSA, which is con-
sistent with the results of Tiemersma et al. [23]
and the 2003 European Antimicrobial Resistance
Surveillance System (EARSS) Annual Report
(http://www.earss.rivn.nl).
Mortality was high in the patient cohort stud-
ied, reaching 30% after 12 weeks. This may best
be explained by the high burden of co-morbidities
in this population. In contrast to other studies, an
increased risk of death was not observed for
Table 2. Complications and outcomes of Staphylococcus
aureus bacteraemia in haemodialysis patients
Complications/outcome
Patients, n (%)
Nosocomial
(n = 49)
Community-
acquired
(n = 60)
Total
(n = 109)
Any complicationsa 7 (14.3) 11 (18.3) 18 (16.5)
Osteomyelitis 2 (4.1) 3 (5) 5 (4.6)
Abscess 0 (0) 3 (5) 3 (2.8)
Meningitis 1 (2) 2 (3.3) 3 (2.8)
Other 4 (8.2) 2 (3.3) 6 (5.5)
Stroke 0 (0) 1 (1.7) 1 (0.9)
Infective endocarditis 0 (0) 1 (1.7) 1 (0.9)
Arthritis 0 (0) 1 (1.7) 1 (0.9)
Septic emboli 1 (2) 0 (0) 1 (0.9)
Outcome
Mortality during hospital stay 15 (30.61) 13 (21.67) 28 (27.8)
Mortality at 12 weeks 18 (36.73) 16 (26.67) 34 (30.6)
Persistent S. aureus infection at
hospital discharge
12 (24.5) 24 (40) 36 (33)
aPatients who had more than one complication were counted only once in the any
complication category.
Table 3. Diagnostic and therapeutic procedures (n, %)
performed for haemodialysis patients with Staphylococcus
aureus bloodstream infection
Procedure
Nosocomial
(n = 49)
Community-
acquired
(n = 60)
Total
(n = 109)
Diagnostic studya
Echocardiography 31 (63.3) 28 (46.7) 59 (54.1)
Trans-thoracic 26 (53.1) 21 (35) 47 (43.1)
Trans-oesophageal 11 (22.4) 10 (16.7) 21 (19.3)
Computed tomography scanb 27 (55.1) 19 (31.7) 46 (42.4)
Magnetic resonance imaging 7 (14.3) 7 (11.7) 14 (12.8)
Abdominal ultrasound
examinationb
42 (85.7) 36 (60) 78 (71.6)
Scintigraphies 6 (12.2) 2 (3.3) 8 (7.3)
Other non-interventional
diagnostic tests
23 (46.9) 25 (41.7) 48 (44)
Interventional diagnostic testsb 21 (42.9) 12 (20) 33 (30.3)
Lumbar puncture 2 (4.1) 2 (3.3) 4 (3.7)
Surgical procedures related to
haemodialysis accessc
Primary arterio-venous ﬁstula 13 (50) 8 (20) 21 (31.8)
Removal 4 (15.4) 0 4 (6.1)
Debridement or drainage 2 (7.7) 3 (7.5) 5 (7.6)
Replacement 11 (42.3) 5 (12.5) 16 (24.2)
Thrombectomy 2 (7.7) 5 (12.5) 7 (10.6)
Polytetraﬂuoroethylene graft 5 (100) 6 (54.5) 11 (10.1)
Removal 1 (20) 1 (9.1) 2 (1.8)
Debridement or drainage 0 2 (18.2) 2 (1.8)
Replacement 4 (80) 3 (27.3) 7 (6.4)
Thrombectomy 0 0 0
Tunnelled cuffed catheter 21 (91.3) 21 (80.8) 42 (85.7)
Removal 10 (43.5) 17 (65.4) 27 (55.1)
Replacement 19 (82.6) 7 (26.9) 26 (53.1)
Temporary catheter 28 (100) 21 (91.3) 49 (96.1)
Removal 27 (96.4) 15 (65.2) 42 (82.4)
Replacement 27 (96.4) 20 (87) 47 (92.2)
aIndicates diagnostic studies performed during the initial admission. Patients with
more than one identical procedure were counted only once for that procedure.
bStatistically signiﬁcant (p <0.05).
cPercentage of patients with this access device who underwent the procedure
during the initial period of hospitalisation.
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patients with MRSA BSI in comparison with
patients with methicillin-susceptible S. aureus
infections. Also, no signiﬁcant difference was
found in the 12-week mortality rate for patients
with nosocomial and community-acquired BSI.
A single-centre study in the USA also investi-
gated the clinical and economic consequences of
S. aureus BSI in haemodialysis patients [9]. While
the patient characteristics were comparable with
those in the present study, there were substantial
differences in various other parameters, including
haemodialysis access at admission (arterio-ve-
nous ﬁstula, 1% vs. 54%; graft, 29.5% vs. 9%),
the proportion of patients treated with vancomy-
cin (70% vs. 27%), and the proportion of patients
with any complication (33% vs. 16.5%) The
incidence (0.9%) of infective endocarditis was
also lower in the present study than reported
previously [9,24], although this may be biased by
the lower usage of trans-thoracic and, especially,
trans-oesophageal echocardiography. There were
no differences in the use of echocardiography
among the three centres in the present study, and
no major differences were noted in the use of
other diagnostic procedures, except for ultra-
sound and other non-interventional diagnostic
tests. Both procedures were used considerably
more frequently in the present study than in that
of Engemann et al. [9].
The total cost of a BSI episode was marginally
higher for patients with older per diem charges
(14 463 vs. 13 913 Euros), and the length of
hospitalisation was slightly longer for the G-
DRG patients (40.3 vs. 34.0 days). Costs for
subsequent hospitalisation periods and outpatient
care accounted for a minor proportion of the total
cost of each episode, as the largest component
was the cost of the initial period of hospitalisation.
The present data show clearly that the main
source of infection in nearly half of the patient
population with S. aureus BSI was a vascular
device. These results highlight the importance of
reducing the frequency of catheter use in haemo-
dialysis patients as much as possible, and using
primary arterio-venous ﬁstulas instead, although
this is not always possible in an ageing and
diabetic population with a limited number of
suitable sites [25]. The percentage of native
ﬁstulas used in Germany is already higher than
in the USA (84% vs. 24%). The higher usage of
grafts and catheters in the USA compared with
the present study (58% vs. 12%, and 17% vs. 4%,
respectively) may explain the differences in infec-
tion rates [26]. In patients without suitable sites
for the formation of a native ﬁstula, it is important
to prevent infection by using appropriate guide-
lines [37]. Quality assurance programmes to
control the complication rates associated with
catheters and ﬁstulas, as well as educational
programmes for patients and staff, are valuable
tools that contribute to reducing infection [28,29].
An effective S. aureus vaccine for haemodialysis
patients could also be helpful in preventing BSI
caused by S. aureus [1].
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